
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's sales demonstrated a significant growth of 29%, reaching $803 million in 2024, with management projecting a continued upward trajectory towards $940-$955 million. The company is also expected to strengthen its market position in the neuromodulation sector, particularly with the aura6000, which has a projected market share increase from 9.0% to 14.9% between 2027 and 2029, corresponding to estimated sales growth from $120 million to $280 million. LivaNova’s robust revenue foundation, bolstered by its strategic focus on cardiopulmonary solutions and neuromodulation devices, provides a solid basis for a positive financial outlook.
Bears say
LivaNova's stock outlook is negatively impacted by anticipated revenue growth slowing to low-single digits due to ongoing challenges in its Neuromodulation and Cardiovascular segments. Additionally, the company is facing operating margin contraction and is projected to deliver earnings below consensus expectations, further compounding financial concerns. Risks to the forecast include the possibility of failing to secure FDA approval for new products, specifically the aura6000, and slower-than-expected growth in both Neuromodulation and Cardiopulmonary divisions.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares